A multidisciplinary expert panel highlighted that maintenance Bacillus Calmette–Guérin therapy can significantly reduce non-muscle-invasive bladder cancer progression when patients can complete treatment without premature discontinuation. The panel emphasized operational steps—proactive toxicity management and structured patient education—to address barriers that cause early stopping. The new emphasis links clinical outcomes to adherence-enabling interventions, reflecting how implementation can materially influence the effectiveness of an otherwise well-known immunotherapy. In parallel, emerging Phase 3 data from cretostimogene further heighten competitive pressure on maintenance strategies. Together, these readouts reinforce a practical point for clinical and commercial teams: treatment duration, patient support systems, and toxicity pathways can determine whether protocols achieve their modeled benefit in real-world settings.